DVN

National Securities (VCI) swung to a pre-tax loss of VND 97B in Q2/2026 from a profit of VND 42B a year earlier, driven by a 50% revenue decline and a 75% increase in operating costs. The loss was primarily due to a near-total collapse in gains from FVTPL financial assets, which fell from VND 96B to just VND 1B. The weak results underscore the impact of adverse market conditions on VCI's proprietary trading and brokerage income.

Vidipha (VDP) will issue 9.94 million shares to existing shareholders at 10,000 VND/share, raising over 99.3 billion VND to invest in a Cephalosporin injection production line targeting EU-GMP standards. The rights offering, with a 100:45 ratio, will increase charter capital from 220.8 billion VND to 320.2 billion VND. Major shareholders including DSC and DVN are expected to participate.

Vinapharm (DVN) posted record pre-tax profit of 825 billion VND in 2025, up 62% YoY and exceeding the plan by 77%. The AGM approved a 10% cash dividend and outlined a strategy focusing on biosimilars and technology transfer, including partnerships with Celltrion and Promomed.